Compare ResMed Inc. (RMD) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Financial Select Sector SPDR Fund — how do they compare? ResMed Inc. trades at $229.88 (market cap $31.89B), while Financial Select Sector SPDR Fund trades at $54.71 (market cap $50.06B). The key difference: Financial Select Sector SPDR Fund is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while Financial Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| RMD | XLF | |
|---|---|---|
Market Cap | $31.89B | $50.06B |
Volume | 618,314 | 47,464,120 |
Sector | Health | — |
52-Week High | $277.88 | $58.55 |
52-Week Low | $182.82 | $47.80 |
Typical Hold Time | 51 Days | 104 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
XLF trades at $54.48, up 1.36% with a bearish technical signal from moving averages. The ETF faces headwinds as financial stocks lag the S&P 500 by the widest margin since 1990 despite rising bank profits. Recent Fed stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
The outlook remains cautious with technical indicators showing bearish momentum. Rising interest rates could benefit financial sector profitability, but regulatory uncertainty and market underperformance relative to broader indices present near-term risks for investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
